Warning Letter — Foshan Miwei Cosmetics Co., Ltd.: Center for Drug Evaluation and Research (CDER)
The FDA issued a Warning Letter to Foshan Miwei Cosmetics Co., Ltd. following an evaluation by the Center for Drug Evaluation and Research (CDER).
This notice affects Foshan Miwei Cosmetics Co., Ltd., specifically their personnel involved in drug manufacturing, quality control, and regulatory compliance for products exported to the U.S. market.
CDER involvement suggests the products manufactured by this cosmetic firm may be classified as drugs under the FD&C Act, necessitating adherence to Current Good Manufacturing Practice (CGMP) regulations. Failure to address these violations may lead to import alerts or the withholding of product entry into the United States. While the source does not detail specific violations, such letters typically indicate significant deviations in manufacturing or labeling.
Review current manufacturing and quality control standards against CGMP requirements for any cosmetic products categorized as drugs. Ensure all site registrations and product listings are current and accurate before exporting to the U.S. market.
FDA issued a Warning Letter to Foshan Miwei Cosmetics Co., Ltd.. Subject: Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/foshan-miwei-cosmetics-co-ltd-722272-04202026
Open in openFDA / FDA.gov